Horizon Omics Biotech is a research-driven high-tech company located in Beihu Technology Park, Changchun, China. It boasts a high-level R&D team centered around overseas PhD scientists, dedicated to developing first-in-class and best-in-class innovative cancer drugs, antiviral medications, and companion diagnostics.
More
Treats approximately 20% of solid tumors with DNA damage repair defects; positioned as a follow-up treatment to PARP inhibitors.
New target drug focusing on nucleic acid advanced structures; a first-in-class innovative drug.
International team of scientists with results from joint research by UBC in Canada and the University of Cambridge.
Excellence Achievements 2022-2023
In the 2023 8th "Maker in China" SME Innovation and Entrepreneurship Competition, Changchun Regional Competition, Horizon Omics Biotech (Changchun) Co., Ltd. won third prize in the enterprise group. Additionally, the new target drug development project in the nucleic acid field by Xinyi Horizon (Beijing) Biotechnology Co., Ltd. received the Excellence Award at the HICOOL 2022 Global Entrepreneurship Competition. Moreover, the company won the Gold Award in the Technology Innovation Special Competition (Startup Group) of the 2022 9th "Chuang Qingchun" Jilin Youth Innovation and Entrepreneurship Competition.
Honors in the 2021 Innovation and Entrepreneurship Competition
Horizon Omics Biotech (Changchun) Co., Ltd. stood out in the 2021 10th Innovation and Entrepreneurship Competition, winning third prize in the "Jilin Division" startup group, and successfully advanced to the national competition, earning the Outstanding Enterprise honor in the startup group. This achievement not only highlights the company's exceptional innovation capabilities in the biopharmaceutical field but also solidifies its leading position in the industry, reflecting our steadfast commitment to excellence and continuous innovation.
